Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 19/20 | 1.00 |
| ▸ | PLG | P00747 | 14/20 | 0.66 |
| ▸ | KLKB1 | P03952 | 13/20 | 0.66 |
| ▸ | PRSS1 | P07477 | 13/20 | 0.66 |
| ▸ | F2 | P00734 | 12/20 | 0.66 |
| ▸ | PLAT | P00750 | 11/20 | 0.66 |
| ▸ | KLK1 | P06870 | 1/20 | 0.54 |
| ▸ | PIR | O00625 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7344370 | 0.83 | PLAU (1.00) | PLAUPLGKLKB1PRSS1F2 | |
| SCHEMBL7340670 | 0.82 | PLAU (0.70) | PLAUPLGKLKB1PRSS1F2 | |
| SCHEMBL6984836 | 0.78 | RAB9A (0.66) | PLAUPIRGSK3BHSF1 | |
| SCHEMBL7335930 | 0.74 | PLAU (0.78) | PLAUPLGKLKB1PRSS1F2 | |
| SCHEMBL691153 | 0.74 | MAPT (0.60) | PLAUPIRGSK3BHSF1 | |
| SCHEMBL7340321 | 0.74 | PLAU (1.00) | PLAUPLGKLKB1PRSS1F2 | |
| SCHEMBL21499352 | 0.74 | PLAU (0.58) | PLAUPIRGSK3BHSF1 | |
| SCHEMBL7430798 | 0.73 | PLAU (0.76) | PLAUPLGKLKB1PRSS1F2 | |
| SCHEMBL27536267 | 0.73 | PLAU (0.81) | PLAUPLGKLKB1PRSS1F2 | |
| SCHEMBL5053574 | 0.73 | PLAU (0.56) | PLAUPIRGSK3BHSF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
| EP-1000018-A2 | UROKINASE INHIBITORS | Abbott Laboratories (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005096-A2 | UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | PLAU 2/4885PLG 10/4885KLKB1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.